ADA 25 - CagriSema shows benefits in obesity and type 2 diabetes in the REDEFINE 1 and 2 trials.

In this video, we are joined by Dr Sue Pedersen (C-endo Diabetes and Endocrinology Clinic, Calgary, CA) to discuss the findings from the REDEFINE 1 and 2 trials which investigated the effect of CagriSema 2.4mg.

Findings showed that CagriSema was associated with weight reduction efficacy across patients with obesity and type 2 diabetes. The combination therapy was generally well-tolerated, with gastrointestinal adverse events being the most common side effects.

Learn more from Dr Pedersen's blog.

Interview Questions: 

1. What were the primary objectives of the REDEFINE Trials?
2. What was the rationale for combining cagrilintide and semaglutide, and how does this dual mechanism approach differ from existing therapies?
3. What was the study design and patient population?
4. What were the key findings?
5. How does CagriSema potentially fit into existing obesity treatment algorithms alongside lifestyle interventions and other pharmacotherapies?
6. How might these findings influence obesity treatment guidelines and clinical practice?

Interviewer: Jordan Rance
Video Specialist: David Ben-Harosh
Recorded remotely from Calgary, 2025.